Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, highlights the annual initiative Strangles Awareness Week - an international awareness campaign aimed at reducing the spread of strangles within the equine industry. In Sweden, the campaign is known as Stoppa kvarkan.

Strangles, caused by the bacterium Streptococcus equi, is the most commonly diagnosed infectious disease in horses worldwide. The disease is highly contagious and can lead to prolonged disruptions to equine operations, with significant economic consequences.

A Shared European Commitment

Strangles Awareness Week (SAW) runs for one week - this year from 4 -10th of May. The campaign originated in the United Kingdom and in recent years has grown into a broad, Europe-wide movement. In Sweden, the campaign is coordinated by the Swedish National Veterinary Institute (SVA) and HästSverige, with support from several organisations and associations within the equine sector. Stakeholders across the Nordic countries are also actively involved, further strengthening cross-border collaboration.

During the past week, Intervacc led an international conference in Edinburgh, bringing together leading veterinarians from around the world to present the latest findings in strangles research and biosecurity. At the meeting, participants agreed on guidelines for disease prevention and management based on best practice, and these guidelines are now being adopted by the countries represented.

Intervacc supports the campaign as part of its long-term commitment to combating strangles, where education in general biosecurity plays a central role - knowledge that makes a tangible difference in everyday stable management.

"Biosecurity is a shared responsibility. The greater the knowledge horse owners and equine businesses have about how infections spread, the greater our ability to prevent outbreaks such as strangles. That is why education and dialogue are a natural part of our work," says Carl-Johan Dalsgaard, CEO of Intervacc.

For more information about the campaign, please refer to the press release from the Swedish National Veterinary Institute (SVA).

For more information please contact:  

Carl-Johan Dalsgaard, CEO

Phone: +46 (0)8 120 10 600

E-mail: carl-johan.dalsgaard@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on May 4th, 2026 at 08.30 CET.

About Strangvac

Strangvac is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.

About Intervacc

Intervacc AB is an animal health group that develops vaccines for animals. The company's vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see intervacc.se

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10